肺腺癌発生過程におけるDNAメチル化変化の解析 by Husni  Ryan Edbert
Identification of DNA methylation alteration
during the course of lung adenocarcinogenesis
著者（英） Husni  Ryan Edbert
内容記述 この博士論文は内容の要約のみの公開（または一部
非公開）になっています
year 2019
その他のタイトル 肺腺癌発生過程におけるDNAメチル化変化の解析
学位授与大学 筑波大学 (University of Tsukuba)
学位授与年度 2018
報告番号 12102甲第9173号
URL http://hdl.handle.net/2241/00156460
論文概要
論文題目 Identification of DNA meth lation alteration durin the course of 
lung adenocarcinogenesis (肺線癌発生過程における DNA メチル
化変化の解析）
指導教員
人間総合科学研究科 生命システム医学専攻 野口雅之教授
（所属）筑波大学大学院人間総合科学研究科生命システム医学専攻
（氏名） Ryan Edbert Husni (ライアン エドバード フスニ）
Abstract 
 
      Lung cancer is still the leading cause of cancer death with varied survival rate. 
Among the histological subtypes, adenocarcinoma is the most frequent. Lung 
adenocarcinoma has been known to show a stepwise progression from precancerous 
lesion, adenocarcinoma in situ (AIS), to invasive adenocarcinoma, and also closely 
correlated with gene aberrations. While many new treatments targeted specific genetic 
aberrations have been developed for advanced stage adenocarcinoma, patients treated 
with them eventually acquire resistance against them, failing to decrease mortality 
rate.  Although studies on early stage lung adenocarcinoma are still scarce, previous 
studies in our group have shown that overexpression of particular genes are correlated 
with progression of lung adenocarcinoma and most of them seems not to have genetic 
aberrations, which means that the abnormality of their expression might be 
epigenetically induced.  
      DNA methylation status has been reported to be correlated with the progression of 
adenocarcinoma. In previous study, our group has demonstrated that overexpression 
of Stratifin (SFN, 14-3-3 sigma) in invasive adenocarcinoma is triggered by DNA 
demethylation at SFN promoter region. Based on this finding, I determined to focus 
on DNA methylation.  
      My first study is about DNA Methyltransferase 3 alpha (DNMT3a), which is a 
key enzyme of the methylation pathway. I used IHC to demonstrate DNMT3a 
expression pattern in lung adenocarcinoma, and also Western blot to confirmed the 
specificity of the antibody used for IHC. Consequently, I found that low DNMT3a 
expression is associated with histologically invasive type and a poor prognosis.  
      Based on the fact of DNMT3a dysfunction, I expected that there would be many 
oncogenes that turn to demethylated status and facilitate tumor progression besides 
SFN. Thus the aim of my second study is to find another differentially methylated 
genes that have the same tendency as SFN, which is correlated with early stage 
adenocarcinogenesis.  
     For that purpose, 3 samples of invasive adenocarcinoma, 3 samples of AIS, and 2 
samples of normal lung tissue were subjected to Infinium methylation array to screen 
extensive DNA methylation profiles across the whole genome. From the results, I 
found that 583 CpG sites showed more than 10% higher methylation rate in invasive 
adenocarcinoma compared to AIS and normal lung. On the other hands, only 23 CpG 
sites including SFN locus showed more than 10% lower methylation rate in invasive 
adenocarcinoma relative to AIS and normal lung. Among the later, we finally selected 
6 CpG sites located in SFN, GORASP2, CD1D, ZYG11A, LOC10099657, and 
Mir656 and validated the result using 21 cases of lung adenocarcinoma by 
pyrosequencing. As a result, SFN, GORASP2, and ZYG11A showed stepwise 
demethylation tendency from normal lung, AIS to invasive adenocarcinoma as I 
expected. Moreover, its methylation rate is conversely correlated with the protein 
expression, suggesting that hypomethylation at those sites might lead to their 
overexpression. I next performed immunohistochemistry of GORASP2 and ZYG11A 
to clarify their clinicopathological implication for lung adenocarcinoma. I 
demonstrated that GORASP2 and ZYG11A show high expression in lung 
adenocarcinoma and were associated with histologically invasive subtype, and a poor 
prognosis. I also found that GORASP2 and ZYG11A are independent prognostic 
factors for lung adenocarcinoma.  
      In this study, I made the status of methylation alteration in lung adenocarcinoma 
clear. DNMT3a expression decreased in invasive adenocarcinoma and methylated 
genes have been widely changed in the course of malignant progression. Even though 
the number of hypomethylated genes in invasive adenocarcinoma was limited 
compared to those of hypermethylated genes, I found overexpression of GORASP2 
and ZYG11A induced by DNA demethylation other than SFN. The epigenetic 
changes of the two genes may have an important function in the progression of lung 
adenocarcinoma. GORASP2 and ZYG11A might be clinically applicable as an 
indicator of prognosis and potential novel target molecule for drug development. 
 	
